Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.
Richard J AuchusOksana HamidiRosario PivonelloIrina BancosGianni RussoSelma F WitchelAndrea M IsidoriPatrice RodienUmasuthan SrirangalingamFlorian W KieferHenrik FalhammarDeborah P MerkeNicole ReischKyriakie SarafoglouGordon B CutlerJulia SturgeonEiry RobertsVivian H LinJean L ChanRobert H Farbernull nullPublished in: The New England journal of medicine (2024)
Among patients with CAH, the use of crinecerfont resulted in a greater decrease from baseline in the mean daily glucocorticoid dose, including a reduction to the physiologic range, than placebo following evaluation of adrenal androgen levels. (Funded by Neurocrine Biosciences; CAHtalyst ClinicalTrials.gov number, NCT04490915.).
Keyphrases